2016 - RAS Dialogue
- Targeting the KRAS G12D Neoantigen to Treat Cancer
The G12D mutation of the oncogene KRAS causes thousands of cancers every year. Steven Rosenberg and colleagues at the National Cancer Institute have treated a patient with metastatic colon cancer by using the patient's own cells to target KRAS G12D.
- Cancer Metabolism: A Conversation with Jason Locasale
Cancers driven by oncogenes such as RAS have metabolic pathways that are significantly altered compared to normal cells. Jason Locasale studies how such differences can be used as vulnerabilities for improved treatments.
- Structure of KRAS4b-PDEδ Complex
The structure of fully modified KRAS4b protein complexed to its chaperone PDEδ has been solved. All the amino acids of KRAS4b are seen, including the entire HVR. The structure shows how PDEδ can bind both farnesylated and geranylgeranylated KRAS4b protein.
- Pancreatic Organoids - A Conversation with Senthil Muthuswamy
Pancreatic cancer organoids can be established from tumor biopsies more quickly and cheaply and with more success than patient-derived xenografts. The organoids mimic patient histopathology and may allow drugs to be optimized for precision medicine.
- Tumor Microenvironment Influences Metabolism of Cancer Cells
Solid tumors have disregulated blood, oxygen, and nutrient supplies that influence metabolism in different parts of the tumors. Attacking these differences will require an intimate knowledge of how cancer cells detect and adapt to their environment.